Back to search

Article

Pirtobrutinib for First-Line Chronic Lymphocytic Leukemia: A Non-Anchored Indirect Comparison Using Reconstructed Patient-Level Data

2026-05-18

Abstract excerpt

<h4>Background: </h4> Pirtobrutinib has recently emerged as a promising first-line treatment option for chronic lymphocytic leukemia (CLL). Unlike currently established regimens, which are generally based on doublet combinations, pirtobrutinib can be administered as monotherapy. Because no head-to-head trials comparing pirtobrutinib with contemporary first-line combinations are currently available, indirect compar...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
ea26eb6f-22b4-5550-b7b6-a4d6543ae434
DOI
10.20944/preprints202605.1136.v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Pirtobrutinib for First-Line Chronic Lymphocytic Leukemia: A Non-Anchored Indirect Comparison Using Reconstructed Patient-Level DataDOI 10.20944/preprints202605.1136.v1
Survival in Patients With Relapsed-Refractory Multiple Myeloma: Indirect Comparison of Six New TreatmentsSemantic proximity
Comparison Between Venetoclax-based and Bruton Tyrosine Kinase Inhibitor-based Therapy as Upfront Treatment of Chronic Lymphocytic Leukemia (CLL): A Systematic Review and Network Meta-analysis.Semantic proximity
Pirtobrutinib at the Crossroads: Shaping Its Future Role in Chronic Lymphocytic Leukemia (CLL) Care.Semantic proximity
Predict progression free survival and overall survival using objective response rate for anti - PD1 / PDL1 therapy developmentSemantic proximity
Matching Adjusted Indirect Comparisons (MAICs) and Systematic Review: Efficacy and Safety of Experimental Chimeric Antigen Receptor (CAR) T-cells versus Axicabtagene ciloleucel (Yescarta) for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma (LBCL)Semantic proximity
Comparison of ibrutinib and idelalisib plus rituximab in real-life relapsed/resistant chronic lymphocytic leukemia cases.Semantic proximity
Low-Intensity and Chemo-Free Treatments in Ph+ ALL: Progression-Free Survival Based on Indirect ComparisonsSemantic proximity
Low-Intensity and Chemo-Free Treatments in Ph+ ALL: Progression-Free Survival Based on Indirect ComparisonsSemantic proximity
Final results on effectiveness and safety of Ibrutinib in patients with chronic lymphocytic leukemia from the non-interventional FIRE studySemantic proximity
First-Line Treatment of IGHV-Unmutated Chronic Lymphocytic Leukemia: A Network Meta-Analysis of Targeted and Chemoimmunotherapy Regimens.Semantic proximity
Matching-adjusted indirect comparison of isatuximab plus carfilzomib and dexamethasone with daratumumab plus lenalidomide and dexamethasone in relapsed multiple myelomaSemantic proximity
Stratified Covariate-Reconstructed Survival (SCRS): Extending Guyot IPD Reconstruction to Preserve Covariate-Outcome Associations for Population- Adjusted Indirect ComparisonsSemantic proximity
Select a neighboring publication to make it the new centre.